Biosero and Virscidian Announce Collaboration for Medicinal Chemistry Applications in Drug Discovery

Biosero, developer of laboratory automation solutions to orchestrate scientific discoveries, and Virscidian, developer of solutions to automate LC/MS (liquid chromatography and mass spectrometry) decision-driven workflows, announced a collaboration and co-marketing agreement through which the companies will support fully automated analytical workflows for medicinal chemistry as well as other scientific applications, including accelerated screening for drug metabolism and pharmacokinetics (DMPK).

Recent AiThority News : AI Content Platform MetatronAI.com Announces New Features and Services

“Thanks to our collaboration with the Biosero team, our customers now have access to a validated Green Button Go plugin that seamlessly integrates our analysis-based intelligence with the ability to physically control the scientific process and instrumentation accordingly.”

Virscidian developed the Analytical Studio platform (including Analytical Studio Professional™ and Analytical Studio Express™ software) to accelerate drug discovery. The software automates analysis of mass spectrometric and chromatographic data to provide actionable intelligence, such as the identity and quantification of compounds of interest, optimal analytical and preparative LC/MS conditions, reaction monitoring, and much more. It also provides users with ranked lists of results to streamline decisions about what steps to take next, and which compounds to move forward in the discovery and development pipeline. Biosero provides Green Button Go^® laboratory automation software to schedule, coordinate, and manage the physical flow of materials, the control of instruments, and the digital flow of information on workstations or throughout entire laboratory facilities.

By working together, Biosero and Virscidian are enabling their customers to easily transfer data between these software platforms so that full medicinal chemistry and analytical workflows can be automated. Software-powered conversion of analytical data into actionable decisions can be used to control which compounds are moved to the next stage, which instruments are tasked to run them, and under what conditions. This approach means that more compounds can be tested and moved into follow-up analysis, reducing or removing the need for human intervention. Biosero and Virscidian are currently working together on more than 10 projects around the world where customers are already realizing the benefits of this collaboration.

NLP News: NLP, NLU, and NLG: The World of a Difference

“At Virscidian, we aim to provide actionable intelligence that streamlines compound synthesis, purification, and screening, enabling scientists to spend their time on the highest-value tasks without compromising laboratory productivity,” said Joseph Simpkins, CEO at Virscidian. “Thanks to our collaboration with the Biosero team, our customers now have access to a validated Green Button Go plugin that seamlessly integrates our analysis-based intelligence with the ability to physically control the scientific process and instrumentation accordingly.”

Ryan Bernhardt, Chief Commercial Officer at Biosero, commented: “Based on our close work with customers in the drug discovery and development space, we know there is high demand in biopharma companies to automate medicinal chemistry applications and accelerate compound screening in areas such as DMPK. We are pleased to join forces with Virscidian as we make this connection between our software platforms to help customers streamline drug discovery from synthesis through to registered material and screening results.”

 Latest Aithority Insights : Microsoft and OpenAI extend Partnership to Bring Supercomputing at Center of AI-powered Experiences

 [To share your insights with us, please write to sghosh@martechseries.com]